With Jazz Pharmaceuticals’ (NASDAQ: JAZZ) remarkable share price increase from a 52-week low of $34.02 to a recent high of $60.00, it makes you wonder how much gas JAZZ has left in the tank. A biopharmaceutical company based in Ireland, JAZZ produces sixteen different medications pertaining to narcolepsy, pain management, oncology, psychiatry, and women’s health.... Continue Reading →